Trial Profile
Phase I Study of Local Radiation and CP-675,206 Administration in Patients With Inoperable Locally Recurrent or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2015
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 02 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Apr 2011 New trial record